Replimune Group (NASDAQ:REPL – Get Free Report) had its price target raised by investment analysts at BMO Capital Markets ...

The FDA has accepted a BLA for treatment with RP1 in combination with Opdivo for patients with advanced melanoma who have ...

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on REPL stock, giving a Buy rating yesterday.Invest with ...

Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment, ...

The investigational advanced melanoma combination therapy consisting of RP1 and nivolumab have a PDUFA action date of July 22 ...

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.

The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for RP1 (vusolimogene ...

Replimune Group Inc (REPL) stock saw a modest uptick, ending the day at $11.85 which represents a slight increase of $1.71 or 16.86% from the prior close of $10.14. The stock opened at $12.6 and ...

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Replimune Group (REPL – Research Report), with a price ...

Replimune Group Inc . (NASDAQ:REPL), currently trading at $11.70, saw its price target increased to $27.00 from $18.00 by BMO Capital, with the firm maintaining an Outperform rating on the stock.

Replimune Group ( REPL, Financials) shares surged 17% to $11.85 as of 10:18 a.m. ET Tuesday after the U.S. Food and Drug ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...